ReviewCurrent treatment options in gastroenterology2018
Botulinum Toxin as a Treatment for Refractory Gastroparesis: a Literature Review.
Review in Current treatment options in gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 30 citations in OpenAlex.
- Gastrointestinal Uses of Botulinum Toxin.Handbook of experimental pharmacology · 2021Trial
- Medical management and differential diagnosis of restrictive eating disorders in men: a case study report with co-produced recommendations.Journal of eating disorders · 2025Article
- Pharmacologic treatments for gastroparesis.Pharmacological reviews · 2025Review
- Assessing academic impact through a bibliometrics analysis: Gastroesophageal reflux disease in the context of obesity treatment and bariatric surgery.SAGE open medicine · 2025Article
- Drugs in focus: Botulinum toxin in the therapy of gastrointestinal disorders in children.Journal of pediatric gastroenterology and nutrition · 2024Article
- EndoFLIP assessment of pyloric sphincter in children: a single-center experience.Translational gastroenterology and hepatology · 2023Article
- Gastroparesis.Gastroenterology · 2022Review
- Management of Gastroparesis.Gastroenterology & hepatology · 2021Article
- United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis.United European gastroenterology journal · 2021Article
- The Scarcity of Literature on the Psychological, Social, and Emotional Effects of Gastroparesis in Children.Children (Basel, Switzerland) · 2020Review
- Diabetic Gastroparesis: Perspectives From a Patient and Health Care Providers.Journal of patient-centered research and reviews · 2019Review
- Systemic Botulism Toxicity Caused by Pyloric Botox Injection to Treat Gastroparesis.Case reports in gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewGastroparesis (GP) is a disorder of gastrointestinal motility which leads to delayed gastric emptying in the absence of mechanical obstruction. Treatment is limited as many patients are refractory to dietary modification and the use prokinetic medications carry significant adverse risks. These limitations necessitate more research into experimental therapies. The purpose of this article is to summarize the known information and guidelines on the diagnosis and management of GP and to review the latest literature on experimental treatments. RECENT
findingsBased on the current available literature, there is conflicting data regarding the efficacy of intra-pyloric botulinum injections (IPBIs) for refractory gastroparesis. There have been many open-label trials showing good clinical response, but the only two randomized controlled trials on the matter showed no objective improvement gastric emptying studies. However, both studies were likely underpowered and changes in gastric emptying may not correlate with symptom improvement. As such, these discouraging findings should not be used to exclude botox from the armamentarium of therapies for refractory GP. More large-scale, double-blinded, multicenter randomized control trials are needed to further validate the long-term efficacy and safety of IPBI, as well as gastric peroral endoscopic myotomy (G-POEM), as compared to gastric electrical stimulation (GES) or surgical intervention (i.e., laparoscopic pylorotomy) for refractory gastroparesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.